Rate Video

GU Cancers 2019 | Concordance of different PD-L1 assays: expression in bladder and kidney cancer

Tian Zhang • 15 Feb 2019

GU Cancers 2019

Bladder Cancer Genitourinary Cancer Kidney Cancer Checkpoint Inhibitors

Tian Zhang, MD, of Duke Cancer Center, Durham, NC, discusses work being presented at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, on the comparability of different PD-L1 assays for both bladder and kidney cancer.

Assessing the impact of ADT in patients with prostate cancer and COVID-19

Tian Zhang • 17 Feb 2021

Identifying predictive markers for checkpoint inhibitor response in kidney cancer

Nivolumab with ipilimumab for mRCC

Tian Zhang • 13 Feb 2020

Characterization of circulating immune cells in metastatic urothelial cancer following treatment

Related Videos

Adjuvant checkpoint blockade in high-risk urothelial and kidney cancer

Thomas Powles • 18 Sep 2021

Areas of unmet need in mUC

Thomas Powles • 18 Sep 2021

Pembrolizumab in combination with sEphB4-HSA (B4) in previously treated mUC

Enrique Grande • 17 Sep 2021

Prostate cancer updates at ESMO 2021: STAMPEDE and PEACE-1

Silke Gillessen • 17 Sep 2021